Skip to main content
Top
Published in: Clinical Rheumatology 3/2004

01-06-2004 | Original Article

Bone mineral density in children with familial Mediterranean fever

Authors: Ali Duzova, Fatih Ozaltin, Alev Ozon, Nesrin Besbas, Rezan Topaloglu, S. Ozen, A. Bakkaloglu

Published in: Clinical Rheumatology | Issue 3/2004

Login to get access

Abstract

The aim of this study was to evaluate bone mineral content (BMC), serum and urinary bone turnover parameters in patients with familial Mediterranean fever (FMF), an autosomal recessive disease characterized by recurrent episodes of inflammation of serous membranes. Demographic characteristics and MEFV mutations were defined in 48 children diagnosed with FMF (23 F, 25 M; median age 7.0 years (3.0–10.0)). We evaluated the blood counts, acute-phase proteins and serum and urinary bone turnover parameters during attack-free periods. The BMC and BA (bone area) of vertebrae L1–L4 were measured by DEXA. Thirty-eight age-, sex- and ethnicity-matched healthy children constituted the control group. Mean L1–L4 BMC in Group I (patients with two mutations) and II (patients with no or single mutations) were 15.49±5.99 g and 15.68±4.89 g, respectively, both significantly lower than the mean L1–L4 BMC of control patients, which was 19.59±6.7 g (p<0.05). Mean L1–L4 BMD in Group I, Group II and the control group were 0.466±0.066 g/cm2, 0.487±0.085 g/cm2 and 0.513±0.079 g/cm2, respectively. Mean z-scores in Group I, Group II and the control group were –1.87±0.74, -1.55±0.92 and –1.39±0.84, respectively. Mean L1–L4 BMD and z-score of Group I were lower than in the control group (p<0.05). ESR and SAA (serum amyloid A) levels were higher in Group I patients: 28.3±14.5 mm/h and 350±62 mg/l in Group I; and 20.5±11.7 mm/h and 190±68 mg/l in Group II, respectively. In conclusion, FMF patients had lower BMC, BMD and z-scores than a control group. We suggest that decreased BMD, BMC and z-score in FMF patients may be secondary to subclinical inflammation.
Literature
1.
go back to reference Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever: A survey of 470 cases and review of the literature. Am J Med 43:227–253PubMed Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever: A survey of 470 cases and review of the literature. Am J Med 43:227–253PubMed
2.
go back to reference The French Consortium (1997) A candidate gene for FMF. Nature Genet 17:25–31PubMed The French Consortium (1997) A candidate gene for FMF. Nature Genet 17:25–31PubMed
3.
go back to reference The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause FMF. Cell 90:797–807PubMed The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause FMF. Cell 90:797–807PubMed
4.
go back to reference Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415CrossRef Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415CrossRef
5.
go back to reference Duzova A, Bakkaloglu A, Besbas N et al (2003) Role of serum amyloid A (SAA) in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed Duzova A, Bakkaloglu A, Besbas N et al (2003) Role of serum amyloid A (SAA) in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed
6.
go back to reference Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMed Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMed
7.
go back to reference Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMed Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMed
8.
go back to reference Tanner JM, Whitehouse RH, Takaishi M (1966) Standards from birth to maturity for height, weight, height velocity and weight velocity: British children 1965. Arch Dis Child 41:454–471PubMed Tanner JM, Whitehouse RH, Takaishi M (1966) Standards from birth to maturity for height, weight, height velocity and weight velocity: British children 1965. Arch Dis Child 41:454–471PubMed
9.
go back to reference Cole TJ, Freeman JV, Preece MA (1995) Body mass index reference curves for the UK. Arch Dis Child 73:25–29PubMed Cole TJ, Freeman JV, Preece MA (1995) Body mass index reference curves for the UK. Arch Dis Child 73:25–29PubMed
10.
go back to reference Yalcinkaya F, Cakar N, Misirlioglu M et al (2000) Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation independent amyloidosis. Rheumatology 39:67–72PubMed Yalcinkaya F, Cakar N, Misirlioglu M et al (2000) Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation independent amyloidosis. Rheumatology 39:67–72PubMed
11.
go back to reference Oliveri MB, Wittich A, Mautalen C, Chaperon A, Kizlanski A (2000) Peripheral bone mass is not affected by winter vitamin D deficiency in children and young adults from Ushuaia. Calcif Tissue Int 67:220–224CrossRefPubMed Oliveri MB, Wittich A, Mautalen C, Chaperon A, Kizlanski A (2000) Peripheral bone mass is not affected by winter vitamin D deficiency in children and young adults from Ushuaia. Calcif Tissue Int 67:220–224CrossRefPubMed
12.
go back to reference Kristinsson JO, Valdimarsson O, Sigurdsson G, Franzson L, Olafsson I, Steingrimsdottir L (1998) Serum 25-hydroxyvitamin D levels and bone mineral density in 16–20 year-old girls: lack of association. J Intern Med 243:381–388 Kristinsson JO, Valdimarsson O, Sigurdsson G, Franzson L, Olafsson I, Steingrimsdottir L (1998) Serum 25-hydroxyvitamin D levels and bone mineral density in 16–20 year-old girls: lack of association. J Intern Med 243:381–388
13.
go back to reference Dode C, Pecheux C, Cazeneuve C et al (2000) Mutations in MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 92:241–246CrossRefPubMed Dode C, Pecheux C, Cazeneuve C et al (2000) Mutations in MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 92:241–246CrossRefPubMed
14.
go back to reference Brik R, Shinawi, Kepten I, Berant M, Gershoni-Barush R (1999) Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 103:1025–1026 Brik R, Shinawi, Kepten I, Berant M, Gershoni-Barush R (1999) Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 103:1025–1026
Metadata
Title
Bone mineral density in children with familial Mediterranean fever
Authors
Ali Duzova
Fatih Ozaltin
Alev Ozon
Nesrin Besbas
Rezan Topaloglu
S. Ozen
A. Bakkaloglu
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0874-y

Other articles of this Issue 3/2004

Clinical Rheumatology 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.